• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Fractyl Health

Fractyl Health

Transformative Metabolic Therapies

  • Investors
  • Clinical Studies
  • Careers
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
Home/Revita

Duodenal mucosal resurfacing (DMR) combined with GLP-1 receptor agonism may eliminate insulin treatment while maintaining glycemic control and improving overall metabolic health in type 2 diabetes

Revita

June 28, 2019 by

April 28, 2019 by

April 28, 2019 by

November 29, 2018 by

November 25, 2018 by

October 28, 2018 by

July 28, 2018 by

July 26, 2018 by

June 28, 2018 by

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Go to Next Page »

Footer

LinkedIn X, formally Twitter Facebook
© 2014-2024 Fractyl Health, Inc. All Rights Reserved.
  • Contact
  • Privacy & Cookie Policy
  • Terms of Use
  • Intellectual Property
  • Transparency in Coverage
logo
  • Our Focus
    • Obesity
    • Type 2 Diabetes
  • Our Platforms
    • Revita
    • Rejuva
  • Our Science
    • Clinical Studies
    • Presentations & Publications
  • Our Company
    • Culture
    • Our Team
    • Careers
  • Our News
    • Media Kit
  • Investors